

# Impact of pharmaceutical intervention in women with epilepsy

<b>Submission date</b> 27/04/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 07/06/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 21/02/2022	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Martha Losada-Camacho

**Contact details**  
Crr 30 45-03 Edificio 450  
Farmacia Oficina 215  
Ciudad Universitaria  
Bogotá  
Colombia  
001  
+57 (0)1 3114445288  
mlosadac@unal.edu.co

## Additional identifiers

**Protocol serial number**  
01-2010

## Study information

**Scientific Title**  
Impact of pharmaceutical intervention in the treatment and quality of life of women with epilepsy: a randomised controlled pragmatic clinical trial

**Acronym**

IPHIWWE

**Study objectives**

Will the intervention of the pharmacist in the therapy of women with epilepsy to optimise treatment and improve their quality of life?

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Local medical ethics committee (Fundación Liga Central Contra la Epilepsia, sede Bogotá, LICCE, Acta 18/2009 Comité de Ética), 11/08/2009, ref: CEI-A1. Acta 18 de 2009

**Study design**

Randomised controlled pragmatic trial

**Primary study design**

Interventional

**Study type(s)**

Quality of life

**Health condition(s) or problem(s) studied**

Epilepsy

**Interventions**

This is a two-armed pragmatic trial. The intervention group will receive usual medical care and are additionally given pharmaceutical care, health education and therapeutic drugs monitoring for six months. The control group continued with standard medical care.

All the patients continued drug treatment prescribed by the physician. Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of the study.

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

Quality of Life in Epilepsy Inventory-31 (QOLIE-31). Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of treatment (six months).

**Key secondary outcome(s))**

Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of treatment (six months):

1. Liverpool Adverse Events Profile

2. Spanish Center for Epidemiologic Studies, Depression Scale
3. Drug related problems

**Completion date**

28/02/2011

## Eligibility

**Key inclusion criteria**

1. Female, over 18 years
2. Diagnosis of epilepsy for more than a year
3. In treatment with antiepileptic drugs
4. Having at least one crisis in the last year
5. Ability to comply with the directions of the study

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

Female

**Total final enrolment**

182

**Key exclusion criteria**

1. Active major psychiatric disorder
2. Physical deficit (e.g., hemiplegia) or mental (e.g., mental retardation), preventing them from answering questionnaires
3. Drug/alcohol dependence
4. Involvement, earlier in the pharmaceutical care program of the institution

**Date of first enrolment**

03/05/2010

**Date of final enrolment**

28/02/2011

## Locations

**Countries of recruitment**

Colombia

**Study participating centre**  
Crr 30 45-03 Edificio 450  
Bogotá  
Colombia  
001

## Sponsor information

**Organisation**  
Universidad Nacional de Colombia (Colombia)

**ROR**  
<https://ror.org/059yx9a68>

## Funder(s)

**Funder type**  
University/education

**Funder Name**  
Universidad Nacional de Colombia (Colombia) - Research Division of Bogotá (DIB) (ref: 202010011419 Quipu Code)

## Results and Publications

**Individual participant data (IPD) sharing plan**  
Not provided at time of registration

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	31/10/2014		Yes	No
<a href="#">Results article</a>		15/02/2022	21/02/2022	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes